Indian Journal of Urology
ORIGINAL ARTICLE
Year
: 2001  |  Volume : 17  |  Issue : 2  |  Page : 132--140

Prospective double-blind randomized controlled trial of terazosin, finasteride and allylestrenol in the management of benign prostatic hyperplasia


Madhu S Agrawal, Monish Aron 
 Departments of Urology, S. N. Medical College, Agra, and All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Madhu S Agrawal
4/18-C, Bagh Farzana, Civil Lines, Agra- 282002
India

Medical management is rapidly becoming a very im­portant part of the armamentarium of the urologist in­volved in the treatment of benign prostatic hyperplasia. The commonest options for medical management include alpha-blockers, 5-alpha reductase inhibitors, and pro­gestational anti-androgens. We present a double-blind randomized controlled trial evaluating the safety and efficacy of terazosin, finasteride and allylestrenol, the prototype drugs in each of these respective categories. A total of 140 patients who satisfied the inclusion and exclusion criteria were inducted into the trial after an informed consent. They were randomized into 4 groups, which received placebo, terazosin, finasteride and allylestrenol respectively for 6 months. Since 29 patients did not complete 6 months of therapy, there were 111 evaluable patients at the end of the study. We found that these 3 drugs produce comparable improvement in symp­tom score (-40%), flow rates (-60%) and PVR (-50%) which is significantly better than that in the placebo group. Both allylestrenol and finasteride bring about a comparable reduction in prostate volume (-23%), which is statistically significant as compared to the placebo and terazosin groups. Terazosin in doses of I and 2 mg/ day was, found to be effiective and well-tolerated in the vast majority of our cases. No adverse effects were seen in the placebo and finasteride groups, while 9.6% in the terazosin group had postural hypotension and 10.7% in the allylestrenol group had some loss of libido, prob­lems which were reversible upon cessation of therapy.


How to cite this article:
Agrawal MS, Aron M. Prospective double-blind randomized controlled trial of terazosin, finasteride and allylestrenol in the management of benign prostatic hyperplasia.Indian J Urol 2001;17:132-140


How to cite this URL:
Agrawal MS, Aron M. Prospective double-blind randomized controlled trial of terazosin, finasteride and allylestrenol in the management of benign prostatic hyperplasia. Indian J Urol [serial online] 2001 [cited 2022 Aug 14 ];17:132-140
Available from: https://www.indianjurol.com/article.asp?issn=0970-1591;year=2001;volume=17;issue=2;spage=132;epage=140;aulast=Agrawal;type=0